全文获取类型
收费全文 | 29706篇 |
免费 | 2696篇 |
国内免费 | 61篇 |
专业分类
耳鼻咽喉 | 188篇 |
儿科学 | 1108篇 |
妇产科学 | 883篇 |
基础医学 | 4136篇 |
口腔科学 | 595篇 |
临床医学 | 3851篇 |
内科学 | 5368篇 |
皮肤病学 | 375篇 |
神经病学 | 3474篇 |
特种医学 | 570篇 |
外科学 | 2907篇 |
综合类 | 573篇 |
一般理论 | 53篇 |
预防医学 | 3866篇 |
眼科学 | 652篇 |
药学 | 1976篇 |
中国医学 | 30篇 |
肿瘤学 | 1858篇 |
出版年
2023年 | 229篇 |
2022年 | 252篇 |
2021年 | 601篇 |
2020年 | 454篇 |
2019年 | 688篇 |
2018年 | 740篇 |
2017年 | 592篇 |
2016年 | 581篇 |
2015年 | 669篇 |
2014年 | 964篇 |
2013年 | 1431篇 |
2012年 | 1980篇 |
2011年 | 2064篇 |
2010年 | 1102篇 |
2009年 | 1058篇 |
2008年 | 1706篇 |
2007年 | 1865篇 |
2006年 | 1853篇 |
2005年 | 1738篇 |
2004年 | 1702篇 |
2003年 | 1507篇 |
2002年 | 1451篇 |
2001年 | 446篇 |
2000年 | 396篇 |
1999年 | 406篇 |
1998年 | 316篇 |
1997年 | 280篇 |
1996年 | 232篇 |
1995年 | 211篇 |
1994年 | 179篇 |
1993年 | 199篇 |
1992年 | 288篇 |
1991年 | 257篇 |
1990年 | 268篇 |
1989年 | 263篇 |
1988年 | 242篇 |
1987年 | 197篇 |
1986年 | 193篇 |
1985年 | 209篇 |
1984年 | 164篇 |
1983年 | 177篇 |
1982年 | 150篇 |
1981年 | 125篇 |
1980年 | 121篇 |
1979年 | 159篇 |
1978年 | 137篇 |
1977年 | 117篇 |
1974年 | 110篇 |
1973年 | 139篇 |
1972年 | 117篇 |
排序方式: 共有10000条查询结果,搜索用时 140 毫秒
1.
Victoria L. Parker Matthew C. Winter John A. Tidy Barry W. Hancock Julia E. Palmer Naveed Sarwar Baljeet Kaur Katie McDonald Xianne Aguiar Kamaljit Singh Nick Unsworth Imran Jabbar Allan A. Pacey Robert F. Harrison Michael J. Seckl 《International journal of cancer. Journal international du cancer》2023,152(5):986-997
Gestational trophoblastic neoplasia (GTN) patients are treated according to the eight-variable International Federation of Gynaecology and Obstetrics (FIGO) scoring system, that aims to predict first-line single-agent chemotherapy resistance. FIGO is imperfect with one-third of low-risk patients developing disease resistance to first-line single-agent chemotherapy. We aimed to generate simplified models that improve upon FIGO. Logistic regression (LR) and multilayer perceptron (MLP) modelling (n = 4191) generated six models (M1-6). M1, all eight FIGO variables (scored data); M2, all eight FIGO variables (scored and raw data); M3, nonimaging variables (scored data); M4, nonimaging variables (scored and raw data); M5, imaging variables (scored data); and M6, pretreatment hCG (raw data) + imaging variables (scored data). Performance was compared to FIGO using true and false positive rates, positive and negative predictive values, diagnostic odds ratio, receiver operating characteristic (ROC) curves, Bland-Altman calibration plots, decision curve analysis and contingency tables. M1-6 were calibrated and outperformed FIGO on true positive rate and positive predictive value. Using LR and MLP, M1, M2 and M4 generated small improvements to the ROC curve and decision curve analysis. M3, M5 and M6 matched FIGO or performed less well. Compared to FIGO, most (excluding LR M4 and MLP M5) had significant discordance in patient classification (McNemar's test P < .05); 55-112 undertreated, 46-206 overtreated. Statistical modelling yielded only small gains over FIGO performance, arising through recategorisation of treatment-resistant patients, with a significant proportion of under/overtreatment as the available data have been used a priori to allocate primary chemotherapy. Streamlining FIGO should now be the focus. 相似文献
2.
3.
4.
5.
6.
7.
8.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献
9.
Mary Ann Richardson Helen M Chao Laura L Read James D Clelland Raymond F Suckow 《American journal of medical genetics. Part B, Neuropsychiatric genetics》2006,(2):195-197
Phenylketonuria (PKU), an inborn error of phenylalanine metabolism, has been shown to be a risk factor for tardive dyskinesia (TD). In male psychiatric patients there was a significant relationship between TD and measures of plasma phenylalanine following ingestion of a standardized phenylalanine dose that was indicative of higher brain availability of phenylalanine in patients with TD. In addition, a medical food formulation consisting of branched chain amino acids, which compete with phenylalanine for transport across the blood-brain barrier, has been demonstrated to be an efficacious treatment for TD. Cumulatively these findings suggested that TD was related to phenylalanine metabolism and thus that sequence variants in the gene for phenylalanine hydroxylase (PAH), the rate-limiting enzyme in the catabolism of phenylalanine, could be associated with TD susceptibility. Genetic screening of PAH in a group of 123 psychiatric patients revealed ten sequence polymorphisms and two mutations, but none appeared to be a significant risk factor for TD. 相似文献
10.